<DOC>
	<DOCNO>NCT00058188</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may prevent bone loss associate long term androgen deprivation therapy . It yet know whether zoledronate combine calcium effective calcium alone prevent bone loss . PURPOSE : Randomized phase III trial compare effectiveness zoledronate combine calcium calcium alone prevent bone loss patient stage III stage IV prostate cancer receive long-term androgen deprivation therapy .</brief_summary>
	<brief_title>Zolendronate Prevention Bone Loss Men w/ Prostate CA Long-Term Androgen Deprivation</brief_title>
	<detailed_description>OBJECTIVES : - Compare bone loss patient receive long-term androgen deprivation therapy stage III IV prostate cancer treat supportive care v without zoledronate . - Compare percentage change lumbar spine hip bone density patient treat regimen . - Compare marker bone formation resorption patient treat regimen . - Compare incidence skeletal event ( pathologic non-pathologic bone fracture , spinal cord compression , surgery bone , radiotherapy bone ) patient treat regimen . - Compare incidence new progressive bone metastatic disease patient treat regimen . - Compare survival rate patient treat regimen . OUTLINE : Patients stratify accord race ( black v ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive zoledronate IV 15 minute day 1 oral calcium gluconate oral cholecalciferol daily . Courses repeat every 3 month 12 month absence toxicity . - Arm II : Patients receive oral calcium gluconate oral cholecalciferol arm I . Patients follow every 3 month . PROJECTED ACCRUAL : A total 72 patient ( 36 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer Stage III IV disease Received least 3 month prior androgen deprivation therapy ( maximum amount/time ) either surgical medical castration Medical castration may intermittent continuous androgen suppression via single combineddrug androgen blockade Continued concurrent androgen deprivation therapy require throughout study participation No bone metastases baseline bone scan PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 1 year Hematopoietic Not specify Hepatic Bilirubin less 3 time upper limit normal ( ULN ) AST ALT less 3 time ULN No chronic liver disease Renal Creatinine great 2.0 mg/dL Other Fertile patient must use effective contraception No Paget 's disease No Cushing 's disease No hyperthyroidism No hyperprolactinemia PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior chemotherapy prostate cancer allow Endocrine therapy See Disease Characteristics More 12 month since prior suppressive dos thyroxine calcitonin More 6 month since prior corticosteroid Concurrent corticosteroid allow ( enrollment study ) Radiotherapy Prior radiotherapy prostate cancer allow Surgery See Disease Characteristics Other More 12 month since prior bisphosphonate therapy ( oral IV )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>osteoporosis</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>